Concordantly, TUSC2 restoration in lung cancer cell lines decreased PD-L1 expression, promoting an anti-tumor immune response and enhancing the efficacy of anti-PD-1 and anti-PD-L1 therapies [47,48,49,50]. This evidence concerns the gene CD274 and lung carcinoma.